Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)

NCT04114825 is registered in ClinicalTrials.gov with RhoVac APS as lead sponsor.

NCT NCT04114825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04114825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)
Lead sponsor
RhoVac APS
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 19, 2019
Completion date
November 30, 2022
Enrollment
180 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer recurrent